Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.

British journal of clinical pharmacology - 1 Jul 2005

Miura Masatomo, Tada Hitoshi, Yasui-Furukori Norio, Uno Tsukasa, Sugawara Kazunobu, Tateishi Tomonori, Suzuki Toshio

Abstract excerpt

AIMS: Lansoprazole is affected by polymorphism of CYP2C19. The aim of this study was to examine the effects of fluvoxamine, a CYP2C19 inhibitor, on the pharmacokinetics of each lansoprazole enantiomer among three different CYP2C19 genotype groups. METHODS: Eighteen healthy subjects, of whom six each were homozygous extensive metabolizers (homEMs), heterozygous extensive metabolizers (hetEMs), or poor metabolizers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Drug Interactions

Share to Fluvoxamine

Share to Lansoprazole

Share to Omeprazole

Source

Open in PubMed Open full text

Identifiers

PMID: 15963095
DOI: 10.1111/j.1365-2125.2005.02381.x
PMCID: PMC1884909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.PMID 15963095Read ↗

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.Semantic proximity Read ↗

Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Semantic proximity Read ↗

Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.Semantic proximity Read ↗

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.Semantic proximity Read ↗

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.Semantic proximity Read ↗

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.